Sangamo Therapeutics Inc (NAS:SGMO)
$ 2.3 0.16 (7.48%) Market Cap: 479.89 Mil Enterprise Value: 468.41 Mil PE Ratio: 0 PB Ratio: 12.23 GF Score: 47/100

Sangamo Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 06:05PM GMT
Release Date Price: $2.16
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. I'm Senior Biotech Analyst at the Barclays. Welcome to Barclays Global Healthcare Conference. It is my great pleasure to introduce our next presenting company, Sangamo Therapeutics.

With us, we have Sandy Macrae, Chief Executive Officer. Sandy, why don't you give a brief intro and then we will dive into the questions?

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Thank you, Gena, and thank you to everyone. It's always a pleasure to come to Miami and the Barclays conference, and to see you again, Gena.

So Sangamo is a fascinating company that's executing and delivering on its promise. We have 3 late phase assets, hemophilia with Pfizer, where they've guided that they will file a BLA in the second half of next year. Fabry, where we're showing some great data that I'm sure you want to talk about, and we will hope to move into Phase III at the end of this year. And sickle cell, where we announced

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot